POSEDEL RHEA J

Director Posedel sold 15,000 shares (15.0K) at $80.72 on 2026-04-16; stock at 52-week high, fundamentals deteriorating

Director Rhea J Posedel sold 15,000 shares (15.0K) for $1,210,800.00 ($1.2M) at $80.72, reducing holdings by 3.5% to 412,000 shares while the stock trades at $80.85—its 52-week high. The sale occurs as AEHR faces material operational headwinds: annual revenue contracted 11.0%, latest quarterly revenue stands at $10,313,000.00 ($10.3M), and the company posted a full-year net loss with latest quarter net income of $-3,203,000.00 ($-3.2M). Posedel's prior timing at this ticker has been constructive—2 of 2 measurable sales executed 90-day windows that saw subsequent stock declines of -24.9% and -29.6%—suggesting the director's historical sales pattern at AEHR has preceded price deterioration. The current sale at peak valuation alongside deteriorating profitability and contracting revenue growth warrants close attention to the directional signal.

Director Rhea J. Posedel sold 30,000 shares of AEHR at $70.00 ($2.1M); stock at 52-week high; prior 2 sells at this ticker were 100% well-timed (90d avg -27.3%)

Director Rhea J. Posedel sold 30,000 shares (427.0K shares remaining, -6.6% of holdings) at $70.00 on 2026-04-09, coinciding with AEHR at its 52-week high of $70.43 after a 65.9% surge in 30 days and 167.6% in 90 days. His prior two sales at AEHR on 2023-07-18 and 2023-07-17 were both well-timed at the 90-day mark (-24.7% and -18.4%, respectively), establishing a 100% success rate in timing declines at this ticker. The company remains unprofitable (net income -$3.2M over latest quarter; annual revenue contracted 11.0%), suggesting fundamentals lag the stock's sharp momentum. The convergence of peak pricing, sustained insider selling pattern, and deteriorating financials warrants attention to whether further declines follow the historical precedent.